Population pharmacokinetics of gabapentin in healthy Korean subjects with influence of genetic polymorphisms of ABCB1

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Pharmacokinetics and Pharmacodynamics

• Publication date

  2017-10-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10928-017-9549-6PMID 29018999
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Population Pharmacokinetic Modelling of Morphine, Gabapentin and their Combination in the Rat

  2016cited by this paper
• Efficacy and safety of gabapentin for uremic pruritus and restless legs syndrome in conservatively managed patients with chronic kidney disease.

  2015cited by this paper
• The efficacy of gabapentin in children of partial seizures and the blood levels.

  2014cited by this paper
• Transport of gabapentin by LAT1 (SLC7A5).

  2013cited by this paper
• Population Pharmacokinetics and Pharmacodynamics of Gabapentin After Administration of Gabapentin Enacarbil

  2013cited by this paper
• Costs, work absence, and adherence in patients with partial onset seizures prescribed gabapentin or pregabalin.

  2012cited by this paper
• An update on ABCB1 pharmacogenetics: insights from a 3D model into the location and evolutionary conservation of residues corresponding to SNPs associated with drug pharmacokinetics

  2011cited by this paper
• Effects of ABCB1 polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy.

  2011cited by this paper
• A Comparison of the Pharmacokinetics and Pharmacodynamics of Pregabalin and Gabapentin

  2010cited by this paper
• A Population Pharmacokinetic Model of Gabapentin Developed in Nonparametric Adaptive Grid and Nonlinear Mixed Effects Modeling

  2009cited by this paper
• The Effect ofMDR1 G2677T/A polymorphism on pharmacokinetics of gabapentin in healthy Korean subjects

  2007cited by this paper
• Pharmacokinetics and bioequivalence evaluation of two gabapentin preparations after a single oral dose in healthy Korean volunteers.

  2006cited by this paper
• Treatment of partial seizures with gabapentin: Double‐blind, placebo‐controlled, parallel‐group study *

  2006cited by this paper
• Gabapentin for Hot Flashes in 420 Women With Breast Cancer: A Randomised Double-blind Placebo-controlled Trial

  2006cited by this paper
• Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial.

  2005cited by this paper
• Pharmacokinetics of gabapentin in paediatric patients with uncontrolled seizures

  2004cited by this paper
• The absorption of gabapentin following high dose escalation.

  2003cited by this paper
• Gabapentin dosing in the treatment of epilepsy.

  2003cited by this paper
• Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients.

  2003cited by this paper
• Digoxin pharmacokinetics and MDR1 genetic polymorphisms

  2003cited by this paper
• Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients.

  2003cited by this paper
• Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P‐glycoprotein

  2002cited by this paper
• The effects of the human MDR1 genotype on the expression of duodenal P‐glycoprotein and disposition of the probe drug talinolol

  2002cited by this paper
• The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients.

  2002cited by this paper
• MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine.

  2002cited by this paper
• P-glycoprotein-mediated efflux of antiepileptic drugs: preliminary studies in mdr1a knockout mice.

  2002cited by this paper
• Population pharmacokinetics of gabapentin in infants and children.

  2001cited by this paper
• Identification of functionally variant MDR1 alleles among European Americans and African Americans

  2001cited by this paper
• MDR1 Genotype-Related Pharmacokinetics of Digoxin After Single Oral Administration in Healthy Japanese Subjects

  2001cited by this paper
• Primary care : epilepsy

  2001cited by this paper
• Physicochemical Profiling (Solubility, Permeability and Charge State)

  2001cited by this paper
• Physicochemical profiling (solubility, permeability and charge state).

  2001cited by this paper
• Gabapentin for Neuropathic Pain: Systematic Review of Controlled and Uncontrolled Literature

  2001cited by this paper
• Frequency of single nucleotide polymorphisms in the P‐glycoprotein drug transporter MDR1 gene in white subjects

  2001cited by this paper
• Early identification of refractory epilepsy.

  2000cited by this paper
• Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability.

  2000influential reference
• Gabapentin in pain management.

  2000cited by this paper
• Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo.

  2000cited by this paper
• Clinical aspects and biological bases of drug-resistant epilepsies.

  1999cited by this paper
• Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy.

  1998influential reference
• Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine.

  1997cited by this paper
• P-glycoproteins and multidrug resistance.

  1996cited by this paper
• Evidence for Intestinal Secretion as an Additional Clearance Pathway of Talinolol Enantiomers: Concentration- and Dose-dependent Absorption in Vitro and in Vivo

  1996cited by this paper
• Characterization of the human ABC superfamily: isolation and mapping of 21 new genes using the expressed sequence tags database.

  1996cited by this paper
• Review of theoretical passive drug absorption models: historical background, recent developments and limitations.

  1996cited by this paper
• Gabapentin

  1995cited by this paper
• Pharmacokinetics of gabapentin in subjects with various degrees of renal function

  1994cited by this paper
• P-glycoproteins: mediators of multidrug resistance.

  1993cited by this paper
• A Saturable Transport Mechanism in the Intestinal Absorption of Gabapentin Is the Underlying Cause of the Lack of Proportionality Between Increasing Dose and Drug Levels in Plasma

  1993cited by this paper
• Physical activity, physical fitness, and psychological characteristics of medical students.

  1991cited by this paper
• Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues.

  1990cited by this paper
• Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues.

  1987cited by this paper
• Simplified calculation of body-surface area.

  1987cited by this paper
• Simplified Calculation of Body-Surface Area

  1987cited by this paper
• Pharmacokinetics and metabolism of gabapentin in rat, dog and man.

  1986cited by this paper
• Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells.

  1986cited by this paper
• Apparent dose-dependent oral absorption of cyclosporin A in rats.

  1984cited by this paper
• Prediction of creatinine clearance from serum creatinine.

  1975cited by this paper

• Effects of Gabapentin on the Treatment of Behavioral Disorders in Dogs: A Retrospective Evaluation

  2024cites this paper
• Development of a Population Pharmacokinetic Gabapentin Model Leveraging Therapeutic Drug Monitoring Concentrations

  2024cites this paper
• Impact of ABCB1 Polymorphisms on Lacosamide Serum Concentrations in Uygur Pediatric Patients With Epilepsy in China

  2021cites this paper
• Extracorporeal Treatment for Gabapentin and Pregabalin Poisoning: Systematic Review and Recommendations From the EXTRIP Workgroup.

  2021cites this paper
• Pharmacogenetic perspectives in improving pharmacokinetic profiles for efficient bioequivalence trials with highly variable drugs: a review

  2020cites this paper
• Les gabapentinoïdes : une revue de la littérature

  2020cites this paper
• Long non‐coding RNA FTH1P3 activates paclitaxel resistance in breast cancer through miR‐206/ABCB1

  2018cites this paper
• Pharmacogenetics‐based population pharmacokinetic analysis of gabapentin in patients with chronic pain: Effect of OCT2 and OCTN1 gene polymorphisms

  2018influential citation